Infectious Disease Pharmacokinetics Laboratory
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
| Type | Research/Clinical Laboratory |
|---|---|
| Headquarters | University of Florida |
| Location | |
Director | Dr. Charles Peloquin |
| Website | Official website |
The Infectious Disease Pharmacokinetics Laboratory (IDPL) is a research facility that is affiliated with the College of Pharmacy at the University of Florida.[1]
Overview
[edit]IDPL focuses on the treatments for infections that include HIV, tuberculosis, and other serious infections. This facility provides therapeutic drug monitoring (TDM) using high-performance liquid chromatography and gas chromatography. IDPL has been in existence for two decades and has developed individualized drug regimens by monitoring a patient's blood plasma or serum for target drug concentrations and then interpreting these results and advising physicians how to adjust a drug's dosage to achieve an optimal outcome. This interdisciplinary method allows IDPL to assess each patient's ability to absorb, metabolize and excrete drugs, which then enables them to recommend customized drug dosages based upon these pharmacokinetic factors as well as the severity of the patient's infection. IDPL primarily focuses on tuberculosis, but they also develop drug regimens for cancer patients with fungal infections, and people with HIV.
The Infectious Disease Pharmacokinetics Laboratory also serves as a national reference center for the determination of serum concentrations for the antimycobacterial, antifungal, and anti-HIV drugs, as well as linezolid.
Leadership
[edit]The director is Dr. Charles Peloquin who has been leading this facility for over 20 years. This facility is unique in that it provides finely detailed interpretations of results as applied to adjusting the drug regimens of individual patients. Dr. Peloquin's research efforts focuses on therapeutic drug monitoring and clinical trials for patients with advanced mycobacterial diseases.[1][2][3][4]
References
[edit]- ^ a b "Infectious Disease Pharmacokinetics Laboratory » College of Pharmacy » University of Florida".
- ^ "Emerging Pathogens Institute - University of Florida". www.epi.ufl.edu. 11 January 2024.
- ^ "Southeastern National Tuberculosis Center".
- ^ "Charles Peloquin » College of Pharmacy » University of Florida".